(Reuters) - June 5 - Quark Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, on Tuesday filed with U.S. regulators to sell 5 million shares in an initial public offering at an estimated price of $12 to $14 a share.
The company said it would use the net proceeds to fund research and product development activities as well as for general administrative activities and working capital.
Read more at Reuters.com Government Filings News
The company said it would use the net proceeds to fund research and product development activities as well as for general administrative activities and working capital.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment